KAYAK2U

November 4, 2011

The good and the bad

It's good that more people are understanding the root causes of the country's growing drug shortage problem…

"Essentially all of the drug shortages that occur in the U.S. arise in the generics market, where profitability is fairly low," Greg Conko, of the Competitive Enterprise Institute in Washington, said by email in response to a request for comment from MedPage Today and ABC News.

"Compounding the problem is the fact that the 'buyers' of the drugs in question aren't patients but third-party payers — insurance firms, pharmaceutical benefit managers, and government health programs — all of which have a strong incentive to drive the prices paid for these products down as low as possible.

"So, for many of these drugs, the market can really only sustain a handful of manufacturers — sometimes just one or two. So, when supply disruptions occur — caused by a shortage of raw materials or more often a quality control problem in a manufacturing facility — there aren't a lot of additional producers in the market to take up the slack," Conko said.

Adding to the problem is Medicare's "statutory price inflexibility," which has established a 6% ceiling on price increases in any six-month period. The cap means that manufacturers have little incentive to bring new production online when shortfalls arise.

"What the executive order won't do — can't do — is address the problems with Medicare's pricing rules or the fundamental underlying structure of the marketplace," Conko continued. "But by trying to prevent 'price gouging,' the executive order could actually serve to make drug shortages even worse," Conko said.

Yeah, it's true, and there's more of it, if you care to read it.

But then, when the subject turns to remedies, it's just more of the same bad old government-control bullshit… 

Legislative and regulatory control is needed to ensure the predictability of manufacturing and supply, [Bruce A. Chabner, MD, of Massachusetts General Hospital] continued.

One "carrot and stick" scenario would be to require generic manufacturers to submit projections for product demand and production capacity, and to build redundancy into their production capacity to accommodate generics. The requirements would be tied to new drug applications, and companies that performed well would get priority review, whereas companies with a poor track record could have their applications denied.

What is it with people that they just can't let markets work?

MikeSoja - November 4, 2011 -- 06:47 pm    Filed in: Health care, Shortages  
« Control…
The professional media »
As Happy As A Clam

Kayak2U.com

msoja RSS 2.0

Other's Pages









Search

Archive

November 2026
M T W T F S S
 1
2345678
9101112131415
16171819202122
23242526272829
30  


  • Books4Sale



    Soja's GoodReads Books4Sale Cheap

  • Category Cloud


  • Tag Cloud